Zantac (Ranitidine) Leads
Connect with individuals who developed bladder, stomach, liver, or other cancers after long-term use of Zantac or generic ranitidine contaminated with NDMA.
Zantac Ranitidine Litigation
Zantac (ranitidine), one of the world's most widely used heartburn and acid reflux medications, was found to contain N-Nitrosodimethylamine (NDMA), a probable human carcinogen. The FDA requested manufacturers withdraw all ranitidine products from the market in 2020 after testing confirmed NDMA levels increased over time and with higher storage temperatures. Lawsuits allege manufacturers including Sanofi, Boehringer Ingelheim, and GlaxoSmithKline knew about the NDMA contamination risk and failed to warn consumers.
Associated Conditions
- Bladder cancer
- Stomach cancer (gastric cancer)
- Liver cancer (hepatocellular carcinoma)
- Esophageal cancer
- Pancreatic cancer
- Kidney cancer
- Colorectal cancer
Claimant Eligibility
- Used Zantac or generic ranitidine regularly for six months or longer
- Diagnosed with cancer potentially linked to NDMA exposure
- Purchase records, prescription history, or pharmacy records for ranitidine
- Cancer diagnosis occurred during or after regular Zantac use
- No other primary known cause of the cancer diagnosis
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Ready to Scale Your Mass Tort Practice?
Tell us about your firm and a mass tort strategist will reach out within one business day.
Trusted by 200+ law firms nationwide